Related Experiment Video

Updated: Jun 3, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy

Sabina A Antoniu1, Antigona Carmen Trofor

  • 1University of Medicine and Pharmacy Gr.T.Popa Iasi, Pulmonary Disease University Hospital, Department of Medicine II - Pulmonary Disease, 30 Dr I Cihac Str, 700115 Iasi, Romania. Sabina.antonela.antoniu@pneum.umfiasi.ro

Expert Opinion on Pharmacotherapy
|April 8, 2011
PubMed

Insights

Long-term inhaled gentamicin therapy effectively treats non-cystic fibrosis bronchiectasis by reducing bacterial load and infections. This approach improves patient quality of life with minimal side effects.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Bronchiectasis, particularly non-cystic fibrosis (non-CF) bronchiectasis, is characterized by irreversible airway dilation, leading to recurrent bacterial infections.
  • Infections by bacteria like Staphylococcus aureus and Pseudomonas aeruginosa are challenging to treat with systemic antibiotics due to reduced drug efficacy in structurally altered airways.
  • Inhaled antibiotic formulations offer a potential alternative, delivering lower doses directly to the affected areas for enhanced bactericidal effect.

Discussion:

  • Previous research indicated inhaled gentamicin's efficacy in reducing bacterial load and local infection in both CF and non-CF bronchiectasis.
  • This study investigates the long-term impact of inhaled gentamicin in non-CF bronchiectasis patients.
  • The focus is on sustained infection control, prevention of subsequent infections, and overall quality of life improvement.

Key Insights:

  • Long-term inhaled gentamicin therapy significantly reduces bacterial load and eradicates infections in non-CF bronchiectasis.
  • Patients experienced a decreased incidence of subsequent infections, indicating a protective effect.
  • Quality of life was markedly improved in patients undergoing this treatment regimen.
  • The treatment demonstrated a minimal risk of adverse side effects.

Outlook:

  • Inhaled gentamicin represents a promising therapeutic strategy for managing chronic respiratory infections in non-CF bronchiectasis.
  • Further research could explore optimal dosing, treatment duration, and combination therapies.
  • This approach may offer a valuable alternative to systemic antibiotics, improving patient outcomes and adherence.

More Related Videos

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...